EP3197441A4 - Pharmaceutical formulation for reducing bladder spasms and method of use thereof - Google Patents

Pharmaceutical formulation for reducing bladder spasms and method of use thereof Download PDF

Info

Publication number
EP3197441A4
EP3197441A4 EP14902616.3A EP14902616A EP3197441A4 EP 3197441 A4 EP3197441 A4 EP 3197441A4 EP 14902616 A EP14902616 A EP 14902616A EP 3197441 A4 EP3197441 A4 EP 3197441A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical formulation
bladder spasms
reducing bladder
reducing
spasms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14902616.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3197441A1 (en
Inventor
David A. Dill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellesley Pharmaceuticals LLC
Original Assignee
Wellesley Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellesley Pharmaceuticals LLC filed Critical Wellesley Pharmaceuticals LLC
Publication of EP3197441A1 publication Critical patent/EP3197441A1/en
Publication of EP3197441A4 publication Critical patent/EP3197441A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP14902616.3A 2014-09-24 2014-09-24 Pharmaceutical formulation for reducing bladder spasms and method of use thereof Withdrawn EP3197441A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/057200 WO2016048301A1 (en) 2014-09-24 2014-09-24 Pharmaceutical formulation for reducing bladder spasms and method of use thereof

Publications (2)

Publication Number Publication Date
EP3197441A1 EP3197441A1 (en) 2017-08-02
EP3197441A4 true EP3197441A4 (en) 2018-05-23

Family

ID=55581626

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14902616.3A Withdrawn EP3197441A4 (en) 2014-09-24 2014-09-24 Pharmaceutical formulation for reducing bladder spasms and method of use thereof

Country Status (13)

Country Link
EP (1) EP3197441A4 (ru)
JP (1) JP2017532301A (ru)
KR (1) KR20170049613A (ru)
CN (1) CN107072971A (ru)
AU (1) AU2014407186A1 (ru)
BR (1) BR112017006141A2 (ru)
CA (1) CA2962004A1 (ru)
IL (1) IL250827A0 (ru)
MX (1) MX2017003878A (ru)
RU (1) RU2017113827A (ru)
SG (1) SG11201702069XA (ru)
WO (1) WO2016048301A1 (ru)
ZA (1) ZA201701772B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7025129B2 (ja) * 2017-05-17 2022-02-24 小林製薬株式会社 筋痙攣治療剤
WO2019240755A1 (en) * 2018-06-11 2019-12-19 Wellesley Pharmaceuticals, Llc Pharmaceutical compositions and methods for weight loss

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130216620A1 (en) * 2010-07-08 2013-08-22 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328060D0 (en) * 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
JP5008206B2 (ja) * 2005-05-20 2012-08-22 オメロス コーポレイション シクロオキシゲナーゼインヒビターおよびカルシウムチャネルアンタゴニストの組成物、ならびに泌尿器科の処置において使用するための方法
JP5535616B2 (ja) * 2006-03-31 2014-07-02 ルビコン リサーチ プライベート リミテッド 口腔内崩壊錠剤のための直接圧縮性複合材
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction
EP2670398B1 (en) * 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
CN103191430A (zh) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 用于缓解尿频的缓释制剂及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130216620A1 (en) * 2010-07-08 2013-08-22 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
ZA201701772B (en) 2018-08-29
SG11201702069XA (en) 2017-04-27
RU2017113827A (ru) 2018-10-24
IL250827A0 (en) 2017-04-30
WO2016048301A1 (en) 2016-03-31
AU2014407186A1 (en) 2017-03-09
MX2017003878A (es) 2017-06-28
EP3197441A1 (en) 2017-08-02
KR20170049613A (ko) 2017-05-10
CN107072971A (zh) 2017-08-18
RU2017113827A3 (ru) 2018-10-24
CA2962004A1 (en) 2016-03-31
BR112017006141A2 (pt) 2018-02-06
JP2017532301A (ja) 2017-11-02

Similar Documents

Publication Publication Date Title
EP3193746A4 (en) Expandable body device and method of use
AU2015254922B2 (en) System and method for the creation and use of visually-diverse high-quality dynamic layouts
EP3230740A4 (en) Marker combinations for diagnosing infections and methods of use thereof
EP3110820A4 (en) Tyk2 inhibitors and uses thereof
EP3104796A4 (en) Method and apparatus for affecting pigmentation of tissue
EP3212184A4 (en) Substituted tetrahydropyrans and method of use
EP3136801A4 (en) Method and device for mobility management of mptcp connection
EP3218005A4 (en) Glycan-interacting compounds and methods of use
AU2015346450B2 (en) Expandable drug delivery devices and method of use
EP3096715A4 (en) Bidirectional stent and method of use thereof
EP3094346A4 (en) Vista antagonist and methods of use
EP3310374A4 (en) GLUTATHION FORMULATION AND METHOD OF USE
EP3212152A4 (en) Method and apparatus for the manufacture of softgels
EP3122424A4 (en) System and method for therapeutic management of cough
EP3416665A4 (en) FORMULATION AND METHOD OF USE
EP3328253A4 (en) TOILET DEVICE AND METHOD OF USE
EP3380525A4 (en) PHARMACEUTICAL FORMULATIONS AND METHODS OF USE
EP3139721A4 (en) System for seed preparation and method of use
EP3319539A4 (en) SURGICAL SYSTEM AND METHOD OF USE
EP3177327A4 (en) Inhibitors of myh7b and uses thereof
EP3200769A4 (en) Non-synthetic emulsion-based lipid formulations and methods of use
EP3152281A4 (en) Defoaming agent and associated methods of use
EP3194377A4 (en) Heterocycle substituted amino-pyridine compounds and methods of use thereof
EP3207945A4 (en) Sustained release formulation of metformin and method for preparing same
EP3216450A4 (en) Pharmaceutical preparation comprising cyclin inhibitor and preparation method thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/60 20060101ALI20180112BHEP

Ipc: A61P 13/06 20060101ALI20180112BHEP

Ipc: A61K 31/192 20060101AFI20180112BHEP

Ipc: A61K 31/616 20060101ALI20180112BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180420

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 13/06 20060101ALI20180416BHEP

Ipc: A61K 31/60 20060101ALI20180416BHEP

Ipc: A61K 31/192 20060101AFI20180416BHEP

Ipc: A61K 31/616 20060101ALI20180416BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603